Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's Disease.

Biomarkers / analysis C-Reactive Protein / analysis Crohn Disease / drug therapy Feces / chemistry Gastrointestinal Agents / blood Humans Leukocyte L1 Antigen Complex / analysis Predictive Value of Tests Prospective Studies Remission Induction Sensitivity and Specificity Ustekinumab / blood

Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775

Informations de publication

Date de publication:
11 2019
Historique:
received: 27 06 2018
revised: 18 02 2019
accepted: 25 02 2019
pubmed: 10 3 2019
medline: 15 12 2020
entrez: 10 3 2019
Statut: ppublish

Résumé

Ustekinumab is approved for treatment of Crohn's disease (CD).

Identifiants

DOI: 10.1016/j.cgh.2019.02.042 PMID: 30851477
pubmed: 30851477
pii: S1542-3565(19)30248-4
doi: 10.1016/j.cgh.2019.02.042
pii:
doi:

Substances chimiques

Biomarkers 0
Gastrointestinal Agents 0
Leukocyte L1 Antigen Complex 0
C-Reactive Protein 9007-41-4
Ustekinumab FU77B4U5Z0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2610-2612

Informations de copyright

Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Auteurs

Ninon Soufflet (N)

Department of Gastroenterology, Lyon-Sud University Hospital, Hospices Civils de Lyon, Pierre Bénite, and University Claude Bernard Lyon 1, Lyon, France.

Gilles Boschetti (G)

Department of Gastroenterology, Lyon-Sud University Hospital, Hospices Civils de Lyon, Pierre Bénite, and University Claude Bernard Lyon 1, Lyon, France; INSERM U1111, International Center for Research in Infectiology, Lyon, France.

Xavier Roblin (X)

Department of Gastroenterology, University Hospital of Saint-Etienne, EA-30 64, Groupe Immunité des Muqueuses et Agents Pathogènes, and Faculty of Medicine of Saint-Etienne, Saint-Etienne, France.

Charlotte Cuercq (C)

Laboratory of Biochemistry, Lyon-Sud University Hospital, Hospices Civils de Lyon, Pierre Bénite, and University Claude Bernard Lyon 1, Lyon, France.

Nicolas Williet (N)

Department of Gastroenterology, University Hospital of Saint-Etienne, EA-30 64, Groupe Immunité des Muqueuses et Agents Pathogènes, and Faculty of Medicine of Saint-Etienne, Saint-Etienne, France.

Anne-Laure Charlois (AL)

Department of Gastroenterology, Lyon-Sud University Hospital, Hospices Civils de Lyon, Pierre Bénite, and University Claude Bernard Lyon 1, Lyon, France.

Remi Duclaux-Loras (R)

Department of Gastroenterology, Lyon-Sud University Hospital, Hospices Civils de Lyon, Pierre Bénite, and University Claude Bernard Lyon 1, Lyon, France.

Pauline Danion (P)

Department of Gastroenterology, Lyon-Sud University Hospital, Hospices Civils de Lyon, Pierre Bénite, and University Claude Bernard Lyon 1, Lyon, France.

Anne Mialon (A)

Laboratory of Biochemistry, Lyon-Sud University Hospital, Hospices Civils de Lyon, Pierre Bénite, and University Claude Bernard Lyon 1, Lyon, France.

Mathias Faure (M)

INSERM U1111, International Center for Research in Infectiology, Lyon, France.

Stéphane Paul (S)

Department of Gastroenterology, University Hospital of Saint-Etienne, EA-30 64, Groupe Immunité des Muqueuses et Agents Pathogènes, and Faculty of Medicine of Saint-Etienne, Saint-Etienne, France.

Bernard Flourie (B)

Department of Gastroenterology, Lyon-Sud University Hospital, Hospices Civils de Lyon, Pierre Bénite, and University Claude Bernard Lyon 1, Lyon, France; INSERM U1111, International Center for Research in Infectiology, Lyon, France.

Stéphane Nancey (S)

Department of Gastroenterology, Lyon-Sud University Hospital, Hospices Civils de Lyon, Pierre Bénite, and University Claude Bernard Lyon 1, Lyon, France; INSERM U1111, International Center for Research in Infectiology, Lyon, France. Electronic address: stephane.nancey@chu-lyon.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Concentrations of Ustekinumab During Induction...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines du sang › Immunoprotéines › Protéine C-réactive › Concentrations of Ustekinumab During Induction...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies inflammatoires intestinales › Maladie de Crohn › Concentrations of Ustekinumab During Induction...
questionsmedicales.fr › Liquides et sécrétions biologiques › Fèces › Concentrations of Ustekinumab During Induction...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents gastro-intestinaux › Concentrations of Ustekinumab During Induction...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Concentrations of Ustekinumab During Induction...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes de surface › Complexe antigénique L1 leucocytaire › Concentrations of Ustekinumab During Induction...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Méthodologie en recherche épidémiologique › Valeur prédictive des tests › Concentrations of Ustekinumab During Induction...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Concentrations of Ustekinumab During Induction...
questionsmedicales.fr › Thérapeutique › Induction de rémission › Concentrations of Ustekinumab During Induction...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Sensibilité et spécificité › Concentrations of Ustekinumab During Induction...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Ustékinumab › Concentrations of Ustekinumab During Induction...